查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301159

生物技术和製药服务外包市场规模、份额和趋势分析报告：按服务、最终用途、地区、细分市场趋势：2023-2030

Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Services (Consulting, Auditing & Assessment), By End-use (Pharma, Biotech), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 133 Pages | 商品交期: 2-10个工作天内

价格

生物技术和製药服务外包市场增长和趋势

GrandView Research, Inc.最新报告显示，到2030年，全球生物技术和医药服务外包市场预计将达到1079.6亿美元。

预计 2023 年至 2030 年该市场将以 5.3% 的复合年增长率增长。COVID-19 大流行对生物技术和製药第三方服务提供商和临床试验产生了重大影响，导致试验延迟、中断和取消。大流行的復苏导致更多地采用基于机器学习 (ML) 的平台、人工智能 (AI)、药品製造自动化和创新研究设计，这将在未来几年改变 CRO 和 CMO 的格局。预料到的。

在竞争日益激烈的环境中，企业正在专注于其核心竞争力，以最大限度地提高资源利用率并促进创新。通过外包非核心职能，我们专注于药物开发和发现等核心能力。因此，一些製药公司正在与各种外包服务提供商合作进行新药开发。例如，2022 年 1 月，单克隆抗体开发商 HaemaLogiX 与 Lonza 建立合作伙伴关係，生产 KappaMab 单克隆抗体，这是一种治疗骨髓瘤的候选药物。生物製药和製药公司对再生医学等新颖和创新疗法的投资以及药物开发服务正在推动研发活动。

对生物製剂和小分子的高需求导致生物技术和药品製造的合同製造组织 (CMO) 和合同製造组织 (CRO) 服务组合不断增长。较小的製药/生物技术公司可能需要大量的专业知识或昂贵的能力来进行自己的开发、製造、监管事务、产品维护、产品设计、开发、产品测试、验证、培训和教育。我们正面临着短缺等挑战。其结果是为 CMO 和 CRO 的发展提供了有利可图的机会。外包服务正在不断增长，并变得更具战略性、针对性和计划性。

这些因素预计将在提高 CMO/CRO 的整体市场份额方面发挥关键作用。价格竞争加剧、监管挑战和专利到期正在降低生物技术和製药行业的利润。有竞争力的服务被认为是公司之间的“战略竞争优势”，因为它们有助于克服这些问题。这些服务为我们的客户节省了成本，因为从长远来看，选择可持续的供应商将带来成本节省。它还有助于节省运营和管理生产和研究设施的时间。研发和製造承包可以降低产品开发成本和产品製造成本。

此外，外包服务有助于克服贸易壁垒，使企业更容易进入国外市场。由于这些优势，一些企业选择外包服务，而不是投资生产设备和僱用技术工人。此外，市场上的几家主要参与者正在实施各种战略举措，例如合作伙伴关係、推出、合併和收购，以扩大其在市场上的服务。例如，2022年4月，Covance母公司LabCorp与细胞和基因治疗技术开发商Xcell Biosciences合作，扩大其细胞和基因治疗研究能力。根据该协议，Labcorp 和 Xcellbio 将合作开展旨在提高细胞和基因疗法的功效和安全性的项目。

生物技术和製药服务外包市场报告亮点

  • 由于欺诈案件增加、知识产权差异和技术创新不断增加，预计到 2022 年，咨询领域将以 19.6% 的份额主导市场。
  • 按服务划分，在发展中地区对仿製药和生物仿製药的日益关注的推动下，其他细分市场预计在预测期内将以 5.3% 的最高复合年增长率增长。
  • 由于价格压力增加和仿製药的兴起，製药公司大量外包其内部业务，预计製药行业在预测期内将以 5.5% 的复合年增长率增长。
  • 另一方面，生物技术领域占有很大的市场份额。这是由于生物技术产品的不断增长。
  • 北美地区主导市场，2022 年收入份额最大，达到 53.5%。这是由于该地区拥有大量的生物技术和製药公司以及 CRO 和 CMO 提供的高质量服务。
  • 由于监管框架的改善、成本节约的巨大潜力以及廉价熟练劳动力的可用性，亚太地区预计在预测期内復合年增长率最高，达到 5.8%。
  • 市场主要参与者已采取多项战略举措来增加其在市场上的影响力。例如，2023年2月，专门从事先进药物输送解决方案的生物技术公司Elektrofi与Thermo Fisher Scientific签订了合同製造协议。此次合作将利用 Thermo Fisher Scientific 的合同製造服务专业知识来支持 Electrophy 的药物输送技术。

目录

第一章 调查方法和范围

  • 市场细分和范围
  • 调查方法
    • 信息采购
  • 信息或数据分析
  • 调查方法
  • 调查范围和假设
  • 市场形成和验证
  • 国家/地区份额的计算
  • 数据源列表

第二章执行摘要

  • 市场展望
  • 分部展望
  • 区域洞察力
  • 竞争考虑
  • 生物技术和製药服务外包市场概况
  • 生物技术和医药服务外包细分市场概况
  • 生物技术和医药服务外包市场竞争格局概览

3.生物技术和製药服务外包市场变量、趋势和范围

  • 市场谱系展望
  • 市场动态
    • 市场驱动力分析
    • 市场约束因素分析
  • 生物技术和製药服务外包市场分析工具
    • 行业分析-波特分析
    • PESTEL 分析
    • 最终用途识别分析
    • 服务价格分析

第四章生物技术和医药服务外包市场：服务评估和趋势分析

  • 细分仪表板
  • 生物技术和医药服务外包市场：2022年和2030年服务波动分析
  • 咨询
    • 2018-2030 年咨询市场收入估算和预测
    • 合规性
    • 修理
    • 质量管理体系咨询
    • 其他
  • 审计与评估
    • 2018-2030 年审计和评估市场收入估算和预测
  • 药事事务
    • 2018-2030 年监管市场收入估计和预测
    • 临床试验提交和产品註册
    • 修理
    • 监管写作和发布
    • 其他
  • 产品维护
  • 产品设计与开发
  • 产品测试和验证
  • 培训和教育
  • 其他

第五章生物技术和医药服务外包市场：最终用途估计和趋势分析

  • 细分仪表板
  • 生物技术和製药服务外包市场：2022 年和 2030 年最终用途变化分析
  • 製药公司
  • 生物技术公司

第六章生物技术和医药服务外包市场：区域估计和趋势分析

  • 生物技术和製药服务外包市场：2022 年和 2030 年区域变化分析
  • 北美
    • 监管框架
    • 2018-2030 年北美生物技术和製药服务外包市场估计和预测
    • 美国
    • 加拿大
  • 欧洲
    • 监管框架
    • 2018-2030 年欧洲生物技术和製药服务外包市场估计和预测
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 监管框架
    • 2018-2030 年亚太地区生物技术和製药服务外包市场估计和预测
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 监管框架
    • 2018-2030 年拉丁美洲生物技术和製药服务外包市场估计和预测
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 监管框架
    • 中东和非洲生物技术和製药服务外包市场估计和预测，2018-2030
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第7章 竞争格局

  • 企业分类
  • 2022 年公司市场份额分析
  • 战略规划
  • 公司简介/名单
    • The Quantic Group
    • IQVIA HOLDINGS, INC.
    • Parexel International Corporation
    • Lachman Consultant Services
    • GMP Pharmaceuticals
    • Concept Heidelberg GmbH
    • Covance, INC.
    • Charles River
    • PRA Health Sciences
    • ICON plc.
Product Code: GVR-1-68038-326-3

Biotechnology And Pharmaceutical Services Outsourcing Market Growth & Trends

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 107.96 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.3% from 2023 to 2030. The COVID-19 pandemic has significantly impacted biotechnology and pharmaceutical third-party service providers as well as clinical trials, resulting in trial delays, suspensions, and terminations. The recovery from the pandemic has led to the increasing adoption of Machine Learning (ML)-based platforms, Artificial Intelligence (AI), automation in drug manufacturing, and innovative trial designs that are projected to transform the CRO and CMO landscape in the coming years.

With rising competitiveness, companies are concentrating on their core capabilities to maximize resources and foster innovation. Focus on their key competencies, such as the development and discovery of new medicines, by outsourcing non-core functions. As a result, several pharmaceutical companies collaborate with various outsourcing service providers for new drug development. For instance, in January 2022, HaemaLogiX, a developer of monoclonal antibodies entered into a partnership with Lonza to manufacture a myeloma drug candidate, KappaMab monoclonal antibody. Biopharmaceutical and pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services.

The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production. Small pharma/biotech companies are facing challenges while performing in-house development, manufacturing, regulatory affairs, product maintenance, product design, and development, product testing and validation, and training and education, such as a lack of substantial expertise and expensive capability. This, in turn, has created lucrative opportunities for the growth of CMOs and CROs. Contract services are growing and becoming strategic, targeted, and planned.

These factors are expected to play a pivotal role in enhancing the share of CMOs/CROs in the overall market. Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services are considered a "strategic competitive weapon" among companies, as these services help overcome these issues. These services offer cost savings to their clients as choosing sustainable suppliers could lead to reduced costs in the long run. They also help save time utilized in the operations and management of a production and research facility. Contract research and manufacturing allow low-cost product development and the manufacturing cost of a product.

Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into the foreign market. Owing to these advantages, several firms choose to outsource services rather than invest capital in production equipment and hiring skilled labor. Furthermore, several key entities in the market are undertaking various strategic initiatives, such as partnerships, service launches, mergers, and acquisitions, to expand their services in the market. For instance, in April 2022, LabCorp, the parent company of Covance, collaborated with a developer of cell and gene therapy technologies, Xcell Biosciences, to expand its research capabilities in cell and gene therapies. Under this agreement, Labcorp and Xcellbio would collaborate on projects aimed at improving the efficacy & safety of cell and gene therapies.

Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights

  • The consulting segment is expected to dominate the market with a share of 19.6% in 2022 owing to a rise in the number of fraudulent cases, discrepancies in intellectual property rights, and a rise in technological innovations
  • Based on service, the others segment is expected to witness the highest CAGR of 5.3% over the forecast period owing to the increasing focus on generic and biosimilar in developing regions
  • The pharma segment is expected to witness a CAGR of 5.5% over the forecast period as the pharmaceutical companies outsource internal activities at a larger scale due to rising pricing pressure, and growth of generics in the industry
  • On the other hand, the biotechnology segment held a significant share of the market. This is due to the expanding biotech product pipelines
  • North America dominated the market and accounted for the largest revenue share of 53.5% in 2022 due to the presence of a large number of biotechnology and pharmaceutical companies and the quality of services offered by the CROs and CMOs in the region
  • In Asia Pacific, the market is anticipated to register the highest CAGR of 5.8% over the forecast period owing to improved regulatory frameworks, high scope for cost savings, and the presence of cheap skilled personnel
  • The key players in the market undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2023, Elektrofi, a biotech company specializing in advanced drug delivery solutions, entered into a contract manufacturing agreement with Thermo Fisher Scientific. This collaboration will leverage Thermo Fisher Scientific's expertise in contract manufacturing services to support Elektrofi's drug delivery technology

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
    • 1.2.1. Information Procurement
  • 1.3. Information or Data Analysis
  • 1.4. Methodology
  • 1.5. Research Scope and Assumptions
  • 1.6. Market Formulation & Validation
      • 1.6.1.1. Country Market: CARG Calculation
  • 1.7. Country Based Segment Share Calculation
  • 1.8. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional Insights
  • 2.4. Competitive Insights
  • 2.5. Biotechnology and Pharmaceutical Services Outsourcing Market Snapshot
  • 2.6. Biotechnology and Pharmaceutical Services Outsourcing Market Segment Snapshot
  • 2.7. Biotechnology and Pharmaceutical Services Outsourcing Market Competitive Landscape Snapshot

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing outsourcing of R&D activities
      • 3.2.1.2. Changing regulatory landscape
      • 3.2.1.3. Increasing focus on core competencies by pharmaceutical and biotechnology companies
      • 3.2.1.4. Growing drug development costs coupled with high clinical development failure rates
      • 3.2.1.5. Increasing mergers and collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Loss of control
      • 3.2.2.3. Data security issues
  • 3.3. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. End-use Perception Analysis
      • 3.3.3.1. Why do you outsource Biotechnology and Pharmaceutical services to CROs?
      • 3.3.3.2. Percentage of outsourcing of different services.
      • 3.3.3.3. Importance of CRO selection parameters (Ranking from 1 to 5, where 1 - least important and 5 - most important).
    • 3.3.4. Service Price Analysis
      • 3.3.4.1. Pricing strategy
      • 3.3.4.1.1. Transactional business models
      • 3.3.4.1.2. Performance-based business models
      • 3.3.4.1.3. Outcome-based business models
      • 3.3.4.2. Consulting rates
      • 3.3.4.3. Heat map for pricing analysis

Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis, USD Million, 2022 & 2030
  • 4.3. Consulting
    • 4.3.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Regulatory Compliance
      • 4.3.2.1. Regulatory Compliance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Remediation
      • 4.3.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Quality Management Systems Consulting
      • 4.3.4.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Auditing and Assessment
    • 4.4.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory affairs
    • 4.5.1. Regulatory affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Clinical Trial Applications & Product Registration
      • 4.5.2.1. Clinical Trial Applications & Product Registration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Remediation
      • 4.5.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Regulatory Writing & Publishing
      • 4.5.4.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Maintenance
    • 4.6.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Product Design & Development
    • 4.7.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Testing & Validation
    • 4.8.1. Product Testing & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis, USD Million, 2022 & 2030
  • 5.3. Pharmaceutical Companies
    • 5.3.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Biotech Companies
    • 5.4.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis

  • 6.1. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis, 2022 & 2030
  • 6.2. North America
    • 6.2.1. Regulatory Framework
    • 6.2.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Regulatory Framework
    • 6.3.2. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Prevalence Insights
      • 6.3.5.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Prevalence Insights
      • 6.3.6.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Prevalence Insights
      • 6.3.7.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Prevalence Insights
      • 6.3.8.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Prevalence Insights
      • 6.3.9.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Competitive Scenario
      • 6.3.10.3. Prevalence Insights
      • 6.3.10.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Regulatory Framework
    • 6.4.2. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Prevalence Insights
      • 6.4.3.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Prevalence Insights
      • 6.4.4.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Prevalence Insights
      • 6.4.5.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Prevalence Insights
      • 6.4.6.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Prevalence Insights
      • 6.4.7.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Prevalence Insights
      • 6.4.8.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Regulatory Framework
    • 6.5.2. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa
    • 6.6.1. Regulatory Framework
    • 6.6.2. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Share Analysis, 2022
  • 7.3. Strategy Mapping
  • 7.4. Company Profiles/Listing
    • 7.4.1. The Quantic Group
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. IQVIA HOLDINGS, INC.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Parexel International Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Concept Heidelberg GmbH
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Covance, INC.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Charles River
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. PRA Health Sciences
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. ICON plc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 12 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 14 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 15 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 17 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 19 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 France Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 21 France Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 23 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 25 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 27 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 29 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 31 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 36 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 China Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 38 China Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 India Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 40 India Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 42 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 44 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 46 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 49 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 51 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 53 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 55 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 58 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 60 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 62 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 64 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Participant's overview
  • Table 68 Financial performance
  • Table 69 Key companies undergoing expansions
  • Table 70 Key companies undergoing acquisitions
  • Table 71 Key companies undergoing collaborations
  • Table 72 Key companies launching new products/services
  • Table 73 Key companies undergoing partnerships
  • Table 74 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation and validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Biotechnology and Pharmaceutical Services Outsourcing Market Outlook, 2018 - 2030 (USD Million)
  • Fig. 11 Biotechnology and Pharmaceutical Services Outsourcing Market Summary, 2021 (USD Million)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Parent Market Outlook
  • Fig. 14 Ancillary Market Outlook
  • Fig. 15 Market driver analysis (Current & future impact)
  • Fig. 16 Market restraint analysis (Current & future impact)
  • Fig. 17 Company market position analysis
  • Fig. 18 Biotechnology and Pharmaceutical Services Outsourcing market, service outlook key takeaways (USD Million)
  • Fig. 19 Biotechnology and Pharmaceutical Services Outsourcing market: Service movement analysis (USD Million)
  • Fig. 20 Consulting market, 2018 - 2030 (USD Million)
  • Fig. 21 Regulatory compliance market, 2018 - 2030 (USD Million)
  • Fig. 22 Remediation market, 2018 - 2030 (USD Million)
  • Fig. 23 Quality management systems market, 2018 - 2030 (USD Million)
  • Fig. 24 Other consulting market, 2018 - 2030 (USD Million)
  • Fig. 25 Auditing and assessment market, 2018 - 2030 (USD Million)
  • Fig. 26 Regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical trial applications & product registration market, 2018 - 2030 (USD Million)
  • Fig. 28 Regulatory writing & publishing market, 2018 - 2030 (USD Million)
  • Fig. 29 Legal representation market, 2018 - 2030 (USD Million)
  • Fig. 30 Other regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 31 Product maintenance market, 2018 - 2030 (USD Million)
  • Fig. 32 Product design & development market, 2018 - 2030 (USD Million)
  • Fig. 33 Product testing & validation market, 2018 - 2030 (USD Million)
  • Fig. 34 Training & education market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 Biotechnology and pharmaceutical services outsourcing market: End Use movement analysis
  • Fig. 37 Biotechnology and pharmaceutical services outsourcing market End Use outlook: Key takeaways
  • Fig. 38 Pharma market, 2018 - 2030 (USD Million)
  • Fig. 39 Biotech market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional outlook, 2018 & 2030
  • Fig. 41 Regional market dashboard
  • Fig. 42 Regional market place: Key takeaways
  • Fig. 43 North America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 47 UK biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 49 France biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 57 China (Mainland) biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 58 India biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)